Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;12(4):375-84.
doi: 10.7497/j.issn.2095-3941.2015.0067.

Dermatofibrosarcoma protuberans: from translocation to targeted therapy

Affiliations
Review

Dermatofibrosarcoma protuberans: from translocation to targeted therapy

Jonathan Noujaim et al. Cancer Biol Med. 2015 Dec.

Abstract

Dermatofibrosarcoma protuberans (DFSP), the most common dermal sarcoma, is a low-grade, slow growing fibroblastic malignant neoplasm that most frequently affects middle aged adults and is characterized by a high local recurrence rate and a low propensity for metastasis. Wide surgical resection or Mohs micrographic surgery (MMS) are the preferred approaches for localized disease, while radiation therapy is warranted for inoperable disease or for cases with positive margins where re-excision is not possible. DFSP is generally regarded as refractory to conventional chemotherapy. Treatment options for systemic disease were limited until the discovery of a unique translocation, t(17;22)(q22;q13) (COL1A1;PDGFB) found in a majority of cases. In recent years, imatinib, a PDGFβR, ABL and KIT inhibitor, has revolutionized systemic therapy in DFSP. In this review, we summarize the epidemiological, clinical, histological and genetic characteristics of DFSP and update the readers on its current management.

Keywords: Dermatofibrosarcoma protuberans (DFSP); Mohs micrographic surgery (MMS); imatinib; targeted therapy; translocation.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

Figures

Figure 1
Figure 1
A large polypoid nodule is presented with a homogeneous firm yellowish white cut surface. The tumor can be seen to expand the entire dermis, and extends into the more superficial subcutis.
Figure 2
Figure 2
(A) Dermatofibrosarcoma protuberans (DFSP). Ill-defined cellular tumor is present within the superficial dermis, close to the squamous epithelium (top left of field) (H&E staining, 20×). (B) Most DFSP infiltrates the dermis and subcutis, but some are deeply infiltrating. This example shows prominent infiltration of skeletal muscle bundles (lower half of field) (H&E staining, 20×). (C) DFSP typically comprises cellular distributions of bland spindle cells with elongated vesicular nuclei and small amounts of fibrillary cytoplasm, in a prominent storiform or ¸cartwheel̓ pattern (H&E staining, 200×). (D) Immunohistochemically, DFSP characteristically shows diffuse and strong expression of CD34. This example also illustrates the linearly oriented tumor strands that infiltrate the subcutaneous fat in a ¸honeycomb̓ pattern (IHC staining, 100×). (E) Tumors may show focal or sometimes prominent myxoid change. As the characteristic storiform architecture is lost, there may be difficulty in establishing a diagnosis of DFSP (H&E staining, 100×). (F) Bednar tumor is characterized by spindle cells in a storiform pattern in which there are scattered pigmented, dendritic melanocytic cells (H&E staining, 400×). (G) In children, giant cell fibroblastoma (GCF) is considered a variant of DFSP, but GCF are typically hypocellular, with bland spindle cells and interspersed tumor giant cells in patternless distributions within myxoid or collagenous stroma (H&E staining, 400×). (H) In fibrosarcomatous transformation, the cells are present in more loosely fascicular distributions or ¸herringbone̓ patterns, and often show more prominent mitotic activity (H&E staining, 100×).

References

    1. Fletcher CDM BJ, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press 2013.
    1. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007;56:968-973. - PubMed
    1. Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, et al. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88:2711-2720. - PubMed
    1. Rutgers EJ, Kroon BB, Albus Lutter CE, Gortzak E. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992;18:241-248. - PubMed
    1. Valdivielso-Ramos M, Hernanz JM. Dermatofibrosarcoma protuberans in childhood. Actas Dermosifiliogr 2012;103:863-873. - PubMed

LinkOut - more resources